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Background: Mesenchymal stem cells (MSC) can serve as carriers to deliver oncolytic measles virus (MV) to ovarian
tumors. In preparation for a clinical trial to use MSC as MV carriers, we obtained cells from ovarian cancer patients
and evaluated feasibility and safety of this approach.
Methods: MSC from adipose tissues of healthy donors (hMSC) and nine ovarian cancer patients (ovMSC) were
characterized for susceptibility to virus infection and tumor homing abilities.
Results: Adipose tissue (range 0.16-3.96 grams) from newly diagnosed and recurrent ovarian cancer patients
yielded about 7.41×106 cells at passage 1 (range 4–9 days). Phenotype and doubling times of MSC were similar
between ovarian patients and healthy controls. The time to harvest of 3.0×108 cells (clinical dose) could be
achieved by day 14 (range, 9–17 days). Two of nine samples tested had an abnormal karyotype represented by
trisomy 20. Despite receiving up to 1.6×109 MSC/kg, no tumors were seen in SCID beige mice and MSC did not
promote the growth of SKOV3 human ovarian cancer cells in mice. The ovMSC migrated towards primary ovarian
cancer samples in chemotaxis assays and to ovarian tumors in athymic mice. Using non-invasive SPECT-CT imaging,
we saw rapid co-localization, within 5–8 minutes of intraperitoneal administration of MV infected MSC to the
ovarian tumors. Importantly, MSC can be pre-infected with MV, stored in liquid nitrogen and thawed on the day of
infusion into mice without loss of activity. MV infected MSC, but not virus alone, significantly prolonged the survival
of measles immune ovarian cancer bearing animals.
Conclusions: These studies confirmed the feasibility of using patient derived MSC as carriers for oncolytic MV
therapy. We propose an approach where MSC from ovarian cancer patients will be expanded, frozen and validated
to ensure compliance with the release criteria. On the treatment day, the cells will be thawed, washed, mixed with
virus, briefly centrifuged and incubated for 2 hours with virus prior to infusion of the virus/MSC cocktail into
patients.
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Ovarian cancer kills more women in the United States
than any other gynecologic malignancy. In 2012, it is
estimated that there will be 22,230 new cases of ovarian
cancer and 15,500 women will die from their disease [1].
Due to the lack of obvious symptoms, most women present
with advanced stage cancer at the time of diagnosis. Front-
line therapy is surgical debulking followed by platinium-
taxane based chemotherapy, however, the majority of
patients relapse within 5 years [2,3]. Residual disease after
initial surgery is the strongest predictor of survival of ovar-
ian cancer patients [4]. In a study of 194 patients, it was
reported that minimizing residual disease through aggres-
sive surgical resection was beneficial, especially in patients
with carcinomatosis [4].
Mesenchymal stem cells (MSC) are multipotent cells
capable of differentiating into cell types of various lineages,
including osteocytes, chondrocytes and adipocytes [5].
They can be isolated and expanded from the bone mar-
row, adipose tissues, cord blood and other tissues. Numer-
ous preclinical and clinical studies are evaluating the
potential of unmodified or genetically modified MSC as a
therapy for graft versus host disease, Crohn’s disease, mul-
tiple sclerosis, tissue repair and as carriers of therapeutic
proteins or oncolytic viruses [6-9].
Replication competent tumor selective viruses from
diverse families are being developed as a novel form of
cancer therapy [10,11]. These viruses are engineered to
express therapeutic transgenes (e.g. granulocyte macro-
phage colony stimulating growth factor GM-CSF) to
enhance host immune response against the cancer, to
synergize with drug or radiation therapy (e.g. cytosine
deaminase, herpes simplex virus thymidine kinase (HSV-
TK), sodium iodide symporter (NIS) or reporter genes to
permit noninvasive nuclear imaging of sites of viral gene
expression (HSV-TK, NIS) [12-15]. Numerous viruses are
in advanced phase II or III testing in a variety of cancers,
either as a single agent or in combination with drugs or
radiation therapy [10,11]. We are developing the live atte-
nuated Edmonston strain of oncolytic measles virus as a
virotherapy agent for ovarian cancer, myeloma, glioma
and mesothelioma [16-20]. Various phase I clinical trials
are in progress evaluating the safety and maximal toler-
ated dose of recombinant MV expressing reporter genes
to enable real time monitoring of the profiles of viral gene
expression using a secreted carcinoembryonic antigen
(MV-CEA) or NIS (MV-NIS) [21,22]. A phase I dose
escalation trial in which MV-CEA (103 to 109 TCID50
virus) was given to patients with Taxol and platinum-
refractory recurrent ovarian cancer was recently completed
[23]. Twenty-one patients were treated with MV-CEA
delivered intraperitoneally via a catheter every 4 weeks for
up to 6 cycles. The virus was well tolerated with no dose-
limiting toxicity or virus induced immunosuppression. Fivepatients had significant decreases in CA-125 levels, and
median survival of patients on study was 12.15 months
(range, 1.3-38.4 months), which compares favorably to an
expected median survival of 6 months in this patient popu-
lation [24]. There was dose-dependent CEA elevation in
peritoneal fluid and serum, suggesting that there was viral
replication, albeit low, in the patients. We have hence
extended our Phase I trial to include the evaluation of
MV-NIS as a single agent (108 and 109 TCID50 per dose,
6 cycles) in ovarian cancer patients with recurrent disease
[25]. The NIS gene encoded by the MV-NIS virus enables
the infected cell to concentrate radioisotopes (e.g. Tc-99 m
pertechnetate, I-125), thus enabling SPECT-CT imaging of
the sites and dosimetric measurements on the level of viral
gene expression. The MV-NIS Phase I trial (Clinicaltrials.
gov number NCT00408590) was recently completed and
closed for data analysis (Galanis, unpublished data).
To further improve viral delivery, we and others have
been exploring the use of cells as carriers of oncolytic
viruses to tumors [9,26-31]. Indeed, virus loaded cell car-
riers have potential advantages as a hybrid form of cellu-
lar and oncolytic virotherapy. Mesenchymal stromal cells
home to sites of inflammation or wound healing and are
being investigated preclinically and clinically for tissue
regeneration or as vehicles for therapeutic proteins and
viruses [32]. In particular, MSC appear to be highly effect-
ive as virus carriers to cancer. Using passively immunized
mice given an intraperitoneal dose of antiviral antibodies,
we have demonstrated that adipose tissue derived MSC
from healthy donors can be infected by MV, home to
ovarian tumor xenografts in athymic mice and exert a
superior therapeutic outcome compared to virus alone
[33]. In preparation for clinical testing of this approach,
we evaluated here the feasibility of expanding MSC from
ovarian cancer patients, 6 recurrent and 3 newly diag-
nosed, and compared their migration and tumor homing
abilities with MSC from healthy donors. In particular, we
were interested to evaluate if NIS imaging could enable us
to monitor trafficking of the MSC in vivo and the speed at
which the cells are able to co-localize with the ovarian
tumors. Finally, we also optimized the MSC-virus loading
protocols and evaluated the safety and efficacy of using
MV infected MSC in passively immunized animals.
Results
Feasibility of harvest and expansion of MSC from ovarian
cancer patients
The ovMSC were generated from adipose tissues surgi-
cally obtained from 6 newly diagnosed and 3 recurrent
ovarian cancer patients scheduled for ovarian cancer re-
section by laparotomy. Following the usual midline skin
incision, approximately 2 cm3 of subcutaneous fat was
excised prior to incision of the fascia. Following confirm-
ation of hemostasis, the prescheduled procedure was
Mader et al. Journal of Translational Medicine 2013, 11:20 Page 3 of 14
http://www.translational-medicine.com/content/11/1/20continued. The adipose tissues were placed into sterile
tubes and processed within 2–5 hours. Healthy donor MSC
were obtained from surgical wastes and frozen in liquid ni-
trogen as previously described [34].
Mesenchymal stem cells were successfully isolated from
adipose tissues obtained from all nine ovarian cancer
patients (Table 1). The amount of fat collected varied sig-
nificantly from less than 0.2 gm up to almost 4 gm. It is
very difficult to count cells from newly processed fat.
However, after culture establishment all samples had simi-
lar growth kinetics with population doublings approaching
one per day similar to our previous report [34]. We saw
no significant differences in the growth kinetics using fat
from newly diagnosed or relapsed patients. We also note
that cultures were successful even using the smallest
amount of fat collected. In four samples (including one
sample that was split), we delayed processing to simulate
real world clinical experiences, where samples often re-
quire additional steps (i.e. travel time or pathology). While
not powered for statistical analysis, we noted that the
growth kinetics were also similar between these and those
processed immediately.
The ovMSC have a phenotype that is characteristic of
MSC, that is, they were positive for CD73 (99.9% of popu-
lation), CD90 (99.9%), CD105 (98.5%), CD44 (100%) and
HLA-ABC (99.0%). They are negative for CD14 (0.8%),
CD45 (1.4%) and HLA-DR (0.8%). The ovMSC population
doublings per day were 1.3 (passage 2), 1.2 (passage 3), 1.2
(passage 4) and 0.9 (passage 5), comparing favorably with
those of hMSC [34]. The differentiation potential of
ovMSC into adipocytes, chondrocytes and osteocytes was
also confirmed, respectively, by Oil-Red-O, Alcian blue
and Alizarin Red staining (Figure 1). Finally, samples were
analyzed using karyotype analysis to look for chromo-
somal alterations. Two of our samples showed karyotypicTable 1 Information on mesenchymal stem cells derived from
Sample ID Disease Process timing
1 Newly Diagnosed Immediate
3 Newly Diagnosed Immediate
4 Newly Diagnosed Immediate
7 Newly Diagnosed Immediate
8 Newly Diagnosed 43 hours
10 Newly Diagnosed Immediate
2 Relapsed 14 hours
5a Relapsed Immediate
5b Relapsed 20 hours
6 Relapsed 11 hours
1Of 20 metaphases, 16 were normal and 4 had trisomy 20.
2Of 30 metaphases, 28 were normal and 2 had trisomy 20 and a balanced three-wa
Adipose tissues were either processed immediately or stored in the refrigerator at 4
of ten samples were found to have abnormal karyotype.abnormality. Surprisingly, the abnormality was similar in
both cases (trisomy 20).
Optimizing protocols for MV infection of MSC
Various physical methods were explored to increase virus
infection or gene expression in hMSC. Cells either under-
went heat shock treatment at 42°C before virus loading,
were exposed to DMSO (incubation with 4% DMSO in
standard media before, during or after MV infection) or
centrifuged with the virus inoculum (500, 1000 or 2000
xg) prior to the standard 2 h virus-cell incubation period
at 37°C. Compared to untreated cells, heat shock and
DMSO treatments did not significantly improve numbers
of MV-infected GFP positive cells (data not shown). In
contrast, centrifugation of virus with MSC prior to the 2 h
incubation period enhanced MV infectivity (Figure 2A).
Infectivity was increased from 40% (no centrifugation) to
70% with 500×g or 1000×g centrifugation. A brief centri-
fugation of 5–10 minutes was optimal with no comprom-
ise on cell viability. Longer centrifugation times negatively
impacted this enhancement in infectivity, presumably be-
cause cell viability was compromised (Figure 2A).
Frozen ovMSC stocks from 3 ovarian cancer patients
(FB6, FB7, FB8) and 3 healthy donors (440, 439B, 251)
were randomly selected for further analysis. The cells
were infected with MV-GFP at MOI of 2 or 4, with and
without centrifugation (1000xg, 10 min) prior to the incu-
bation period. The percentage of GFP positive MSC was
determined by flow cytometry 48 h later (Figure 2B). As
expected, the numbers of infected cells increased with in-
creasing amounts of virus with peak infectivity at MOI 4.0.
There was variability in donor cell susceptibility to MV in-
fection. Regardless of the source of MSC (healthy donor
versus ovarian cancer patients), some MSC had intrinsic-
ally poorer infectivity (30%) compared to the others (70%).ovarian cancer patients











y translocation involving chromosomes 1, 10 and 13.
°C before collagenase digestion. Expanded MSC were karyotyped and two out
Figure 1 Ovarian cancer patient derived MSC (ovMSC) retains multi-potent lineage. Representative results of in vitro differentiation of MSC
into adipocytes, osteocytes and chondrocytes post culture in differentiation media. Respective stains used are as indicated. hMSC: healthy
donor MSC.
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cancer cells
The Roche xCELLigence system was used to monitor the
dynamic migration of MSC towards chemoattractants in
real time over 12–48 hours. The system was first validated
using media supplemented with fetal bovine serum (FBS).
There was minimal migration of MSC towards media
supplemented with no FBS (Figure 3A, B) or 0.5% BSA
(Figure 3C). As expected, the rate and extent of MSC mi-
gration is dependent on the concentration of the chemo-
attractant added. With increasing amounts of FBS, there
was a corresponding increase in the rate and numbers of
MSC that migrated across the transwells within 4 hours
of exposure (Figure 3A).
To compare the migration abilities of hMSC and ovMSC
in vitro, 5% FBS in media was used as a chemoattractant.
As shown in Figure 3B, ovMSC and hMSC migrated at
comparable rates and no detectable migration occurred
in the absence of FBS. Migration of MSC towards condi-
tioned media from a human ovarian cancer cell line, SKO-
V3ip.1, and conditioned media from primary ovarian cancer
cells from surgical samples (AMHAK095, AMNMC313,
AMEB166), was also tested. The rates of MSC migration
towards SKOV3ip.1 or primary ovarian cancer cells were
plotted and found to be comparable for hMSC and
ovMSc (Figure 3C). For most MSC, migration reached
steady state within 3 hours of exposure to the condi-
tioned media.Homing of hMSC and ovMSC to ovarian tumor xenografts
We previously demonstrated that hMSC home to ovarian
tumors post i.p. administration into mice with SKOV3ip.1
xenografts [33]. To confirm that ovMSC can co-localize
with ovarian tumors and deliver oncolytic MV, athymic
mice with omental and disseminated peritoneal SKO-
V3ip.1 tumors were given MSC440 or ovMSC (FB6, FB7
or FB8) i.p. at 7 days post-implantation. Mice were har-
vested on days 1, 3, and 10 post MSC administration.
Multimodality imaging was used to identify the various
components; cyan fluorescent protein (CFP) was used to
identify the SKOV3ip.1 cells, lipophilic DiR dye was used
to label MSC for fluorescence imaging at 756 nm, and
oncolytic MV-RFP expresses RFP to facilitate identifica-
tion of areas of viral gene expression. As shown in Figure 4,
there was good co-localization of DiR labeled MSC with
the CFP positive tumor nodules and RFP expression from
MV infection. Measles virus infected ovMSC clearly were
able to home to SKOV3ip.1 tumor nodules.
MSC tumorigenicity study in SCID beige and athymic
mice
To determine if MSC are tumorigenic, SCID beige mice
were injected either subcutaneously or i.p. with the max-
imum feasible number of hMSC which had been deliber-
ately passaged for extended periods in culture. Three
separate lots of hMSC were collected and purified from
adipose tissues of three different healthy donors. These
Figure 2 Centrifugation improves MV infectivity of MSC. (A) MV-GFP
and hMSC were centrifuged at the speeds and times indicated prior to
a 2 h incubation period. Percentage of GFP positive cells were analyzed
48 h later. (B, C) Percentage of MV-GFP infected MSC from healthy
donors (440, 493B, 251) or ovarian cancer patients (FB6, FB7) at MOI of
2 (B) or 4 (C). 1000 xg centrifugation for 10 mins. Representative data
from duplicate experiments.
Mader et al. Journal of Translational Medicine 2013, 11:20 Page 5 of 14
http://www.translational-medicine.com/content/11/1/20hMSC had been cultured for more than 25 population
doublings, representing potential cell expansion to more
than 1012 cells. Mice were injected subcutaneously with
2 × 107 MSC or 4 × 107 i.p. As a positive control, some
mice received SKOV3 human ovarian tumor cells. Mice
were monitored for signs of tumor formation due tohMSC administration. All mice (n = 3 per MSC cohort)
that received hMSC subcutaneously showed no signs of
tumor development at the end of the study (90 days).
Their body condition remained excellent, no adverse clin-
ical signs were seen and all mice continued to gain weight
during the study (Figure 5). In contrast, control mice re-
ceiving SKOV3 developed tumors at the injection site.
Their body condition was fair, but the effect of the tumor
growth was evident from their body weight measurements
showing minimal to no gain in body weight (Figure 5).
Mice that received hMSC i.p. showed no signs of ill health
(n = 6 per MSC cohort). Their body weight continued to
increase, mice appeared healthy and remained active
throughout the study. At the end of the study, mice were
examined for the presence of tumors or growths. While
no tumors were seen, a small white colored deposit was
seen either on the omentum or pancreas in all mice given
hMSC i.p. In some instances, these deposits were found as
an adhesion to the peritoneal wall or inguinal fat pad.
Histology was performed on the deposits and through
H&E and Masson-Trichrome staining, these deposits
appear to be acellular connective tissue which stained
positive for collagen with Masson-Trichrome (data not
shown).
To determine if MSC promote tumor growth, athymic
mice received MSC, SKOV3ip.1 (n = 15 mice) or a cocktail
(1:1 ratio) of MSC and SKOV3ip.1 cells (n = 13 mice).
MSC given at the same time as tumor cell implantation
did not promote tumor growth (Figure 5). There was
no apparent difference in clinical symptoms (e.g. ascites
formation, jaundice, weight loss) noted in mice from
the treatment groups. Survival curves of both treatment
groups were not significantly different from each other
(p = 0.3670, log-rank Mantel-Cox test).
NIS mediated SPECT-CT imaging of MSC co-localization
with tumors in vivo
NIS expression enables the cell to concentrate radioiso-
topes (e.g. Tc-99 m pertechnetate, radioiodine) against
the concentration gradient, thereby enabling noninvasive
imaging of sites of MV-NIS gene expression [25,35]. Here,
we exploited this technology to monitor the kinetics of
MSC trafficking after i.p. administration into tumor bear-
ing mice. Location of the implanted ovarian tumors was
detected using bioluminescent imaging for SKOV3ip.1-
FLuc tumor nodules (Figure 6). The MSC were infected
with MV-NIS for 24 hours after which the cells were
loaded with I-125 and given to mice. The amount of
radioiodine uptake was about 25 μCi per 106 MV-NIS
infected MSC.
No radioactive signals were seen in the tumor bearing
mouse that received uninfected MSC as the cells did not
concentrate I-125 (0.2 μCi per 106 MSC). In contrast,
strong radioactive signals were seen in mice that received
Figure 3 Dynamic real time monitoring of MSC migration using the xCELLigence chemotaxis assay. (A) The extent of hMSC migration is
dose dependent on the concentration of fetal bovine serum (FBS) in the media. FBS concentration ranged from no FBS to 20% FBS in alpha-
MEM. (B) Migration of hMSC or ovarian MSC (FB6-8) towards alpha-MEM supplemented with 5% FBS. Migration of ovMSC (C) FB7 or (D) FB8
towards conditioned media harvested from SKOV3ip.1 ovarian cancer cell line or from primary ovarian cancer cells isolated from clinical
specimens (AMHAK095, AMEB166). Representative data from duplicate experiments.
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In non-tumor bearing mice, the radioactive signals were
more diffused around the peritoneal cavity (Figure 6).
Bioluminescent imaging revealed the presence of omental
tumors and some disseminated peritoneal tumors in tumor
bearing animals (Figure 6). Through SPECT-CT imaging,
we detected rapid localization of the I-125 pre-loaded
MV-NIS/MSC cells at the omental tumor and peritoneal
tumors, showing good concordance with the biolumines-
cent tumor images (Figure 6). Since these SPECT-CT
images were taken within 5–8 minutes of cell infusion,
it is apparent that the rapid localization of MSC with
tumors is perhaps more dependent on cell-to-cell con-
tact interactions rather than chemotactic attraction in
this setting.
Optimizing in vivo delivery of MV by MSC
The optimal MSC platform for MV delivery was evalu-
ated in athymic mice bearing orthotopic intraperitoneal
SKOV3ip.1 tumors. Since most ovarian cancer patients
enrolled in the clinical trial would be measles immune
either from previous vaccination or natural measles in-
fection, mice were passively immunized by i.p. adminis-
tration of pooled measles-immune human serum (50 EUper mouse) to mimic the measles immune status of the
patients. Mice were then given equal numbers (105) of
MV or MV infected MSC. Three different MSC platforms
were tested; using actively growing MSC infected with
MV-NIS, using freshly thawed MSC that had previously
been infected with MV-NIS for 2 h prior to freezing, or
using MSC that had been lethally irradiated (20 Gy) prior
to infection with MV-NIS. For all MSC groups, virus in-
fection was performed at MOI 4.0, with a brief centrifu-
gation prior to the 2 h incubation period to improve virus
infection (Figure 2A), after which the cells were washed
and either used immediately (actively growing or irra-
diated groups) or frozen for storage in liquid nitrogen
(freeze/thaw group). To ensure neutralization of surface
bound virus, the MSC were incubated in vitro with
measles-immune serum (50 EU) for 30 minutes at 37°C
before injection in the animals. Thus, each mouse received
a total of 100 EU of measles immune human sera.
The Kaplan Meier survival curves of mice and the p
values comparing differences between treatment groups
are shown in Figure 6. The median survival for saline
control was 36 days (n = 8 mice), MV was 37 days (n = 8
mice), MV/MSC (actively growing) was 84 days (n = 9
mice), MV/MSC (freeze/thaw) was 72 days (n = 8), MV/
Figure 4 Multimodality imaging showing co-localization of MV infected MSC with peritoneal human ovarian xenografts post
intraperitoneal administration. (A) SKOV3ip.1 tumors were stably expressing cyan fluorescent protein (CFP), MSC were labeled with DiR, and
infected with measles virus expressing red fluorescent protein (MV-RFP). Representative images from mice that received MSC from healthy donor
(hMSC 493B) or ovarian cancer patient (FB8) showed good co-localization of MV infected MSC with the tumors. (B) Tumors from mice were
harvested at day 10 and examined for RFP expression. MV-RFP infected MSC were found on the tumors. Images of tumor nodules were taken at
40X magnification under a fluorescence microscope with a green filter or under bright-field. (C) Quantitative measurement of the amount of CFP
(tumors), DiR (MSC) or RFP (MV infection) fluorescence in mice given MV infected hMSC or ovMSC.
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Figure 5 Safety study to evaluate the tumorigenic potential of MSC in beige SCID and athymic mice. MSC from three different healthy
donors (MSC lot numbers as indicated) were cultured deliberately to more than 25 passages. Mice received 4×107 MSC/500 μl saline
intraperitoneally (n = 6 mice per cohort MSC) or subcutaneously (2×107 MSC/100 μl saline, n = 3 mice/cohort of MSC). Body weights of mice that
received (A) intraperitoneal or (B) subcutaneous MSC were recorded at regular intervals. (C) In the subcutaneous model, size of the ‘lump’ formed
from the MSC deposit was recorded in two dimensions and volume calculated. (D) Body weights of the control mice that received SKOV3 tumor
cells (2×106 cells/100 μl). (E) Growth of SKOV3 subcutaneous tumor in control mice. (F) Survival curve of athymic mice given 106 SKOV3ip.1
(n = 15 mice) or a cocktail of 106 SKOV3ip.1 and 106 MSC (n = 13 mice) intraperitoneally.
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immune animals has no therapeutic activity (Figure 6).
All but one mouse in the saline and MV groups (15 out
of 16) were euthanized because they developed bloody
ascites, with extensive dissemination of ovarian tumors
in the peritoneal cavity, perigastric area, and on the peri-
toneal side of the diaphragm. In contrast, survival curves
of mice treated with all three MV/MSC platforms were
significantly extended compared to MV or saline. In
contrast to the saline and MV groups, only 28% of mice
in the MV/MSC, MV/MSC freeze/thaw, and MV/MSC
RT groups developed ascites (7 of 25). Examination at
necropsy indicated tumor obstruction or constriction ofthe gastrointestional tract around the gall bladder or bile
duct as the cause of euthanasia of these mice. The
remaining animals were euthanized due to weight loss of
more than 20%. At the conclusion of the study at day
90, a number of mice from all the MSC/MV treatment
groups were still alive and appeared healthy (9 of 25).
Discussion
Oncolytic measles virus has promising antitumor activity
and is being investigated as an experimental cancer
therapeutic in various Phase I clinical trials [21,36]. In
athymic mice bearing intraperitoneal ovarian cancer, we
showed that repeat dosing of a recombinant oncolytic
Figure 6 Antitumor activity of MV-NIS or MV-NIS infected MSC in athymic mice passively immunized with human measles immune
sera. (A) Bioluminescent and SPECT-CT imaging show rapid co-localization of Tc-99 m-pertechnetate loaded MV-NIS infected MSC (MSC-NIS) with
luciferase positive SKOV3ip.1 tumors. (B) Mice with SKOV3ip.1 tumors were passively immunized with measles immune human sera and given 105
TCID50 MV-NIS or 10
5 MV-NIS infected hMSC at 7 days post-tumor implantation. RT = MSC were given 20 Gy radiation immediately before MV-NIS
infection. F/T = Frozen stock of MV infected MSC was thawed, washed and used immediately. Actively growing =MSC were in log phase of
expansion prior to MV-NIS infection. (C) p values comparing the survival curves of the respective groups are indicated (Log rank test, Mantel Cox).
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antigen (MV-CEA) virus resulted in significant extension
in survival of mice [19,37]. A Phase I clinical trial in which
MV-CEA was given i.p. to patients with recurrent ovarian
cancer was recently completed [23]. Dose limiting toxicity
was not reached in this dose escalation trial in which
6 cycles of 103 to 109 TCID50 of MV-CEA was given [23].The best objective response was dose-dependent disease
stabilization in 14 of 21 patients with a median duration of
92.5 days (range, 54–277 days). Median survival of patients
on study was 12.15 months (range, 1.3-38.4 months).
To improve therapeutic outcome using MV therapy,
we focused on maximizing delivery of the virus by using
tumor homing cell carriers. We evaluated numerous cell
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derived monocytes [39], but chose adipose tissue derived
MSC due to their ability to be infected by MV and co-
localization with ovarian tumors. In contrast to naked
virus, these MV infected MSC significantly extended the
survival of measles immune tumor bearing mice [33].
There are also well established standard operating proce-
dures in place for harvest, isolation, culture, expansion
and banking of adipose tissue derived MSC in the Human
Cell Therapy Laboratory of our institute (A. Dietz). The
feasibility and safety of using autologous or allogeneic
MSC in humans has been confirmed in a number of phase
II and III studies. For example, infusion of autologous
MSC in patients with ischemic stroke (2 doses, 5×107
cells/dose, intravenous) or multiple sclerosis and amyo-
trophic lateral sclerosis (6×107 cells intrathecally or intra-
venously) or allogeneic MSC to patients with myocardial
infarction (0.5 to 5 ×106/kg intravenous) showed that
autologous or allogeneic MSC can be safely adminis-
tered and tolerated in humans [40-42].
A potential concern with MSC administration is that
the cells could be tumorigenic or promote the growth of
tumors. Since MSC used in our study will be infected by a
replicating virus, the cells typically die within 5 days from
virus infection [33]. In safety studies using athymic mice
given a cocktail of ovarian cancer cells and MSC, we
showed here that the survival of mice was not significantly
different from mice that received tumor cells only. Im-
munocompromised beige SCID mice were also implanted
with large numbers of MSC (4×107 cells/25 gram mouse,
1.6×109/kg) that had been deliberately passaged in culture
for more than 25 passages, representing cell expansion to
more than 1012 cells. No tumor growth was seen in mice
given MSC subcutaneously or i.p. when necropsied at the
end of 90 days, concurring with results from other pub-
lished reports [43]. In mice that received large numbers of
MSC i.p., a white acellular tissue was seen in the omentum
or pancreas, sometimes as an adhesion to the peritoneal
wall or inguinal fat pad. Histological analysis using H&E
staining and Masson-Trichrome staining revealed that
these deposits were acellular connective tissue composed
of collagen (positive staining for collagen with Masson-
Trichrome stain). The significance of the ‘connective tis-
sue’ is not known, but since MSC home to the omentum
post i.p. delivery, we suspect that the deposit represents
remnants of the extracellular matrix from the large num-
bers of cells that have homed to the omentum and died
eventually.
Results of this study confirmed that it is highly feasible
to isolate and expand MSC from ovarian cancer patients,
can be infected by MV, home and deliver the virus to
tumor nodules in athymic mice. For our clinical trial, we
plan to use autologous patient derived MSC to deliver
oncolytic MV in this first-in-human study. The MSCshave a population doubling time that is comparable to
MSC from healthy donors and we aim to expand and
bank sufficient cells for repeat cycles of treatment (aim-
ing to bank >109 cells per patient). One puzzling finding
in our study was the abnormal karyotype of trisomy 20
in the expanded MSC from two of the nine patients. In
total, we have tested the karyotype in more than 20 indi-
viduals with a variety of diseases including amyotropic
lateral sclerosis, Type I diabetes, critical limb ischemia
without detection of karyotypic abnormality. Thus, this
finding of trisomy 20 in MSC of two ovarian cancer
patients is puzzling. Since we did not test the MSC
karyotype at harvest, it is not clear if the cells acquired
trisomy 20 during expansion in culture. The three instances
of viable trisomy are trisomy 21 (Down’s syndrome), tri-
somy 13 (Patau syndrome) and trisomy 18 (Edward’s syn-
drome). Complete trisomy 20 is not viable but trisomy 20
mosaicism is estimated to occur in 1 out of 7,000 pregnan-
cies detected prenatally from amniocentesis or chorionic
villus sampling [44]. However, the outcome is normal in
90-93% of prenatally diagnosed cases. Trisomy 20 were
noted in non-cancer smokers and mine workers where it
was shown they universally harbor increased numbers of
abnormal cells within their airway epithelium [45,46].
Approximately 50% of ovarian tumors and cell lines
have copy number increases in 20q [47], genes ampli-
fied therein, including EEF1A2, may play a central role
in the pathogenesis of sporadic and hereditary ovarian
carcinoma [46]. Currently, the significance of trisomy
20 in the expanded MSC of the ovarian cancer patients
is not clear but will be the subject of further investiga-
tions. In the event that the expanded MSC from the
clinical trial fail to meet the release criteria of normal
karyotype, the patient will not receive MSC/MV ther-
apy but virus alone.
In this study, we also explored the feasibility of using
virus-preinfected cells as the frozen cell bank. In vitro
assays indicated that the virus infected cells will proceed
to express the viral genes and progeny post thaw from
cryopreservation in liquid nitrogen. As shown in this re-
port, actively growing MV-infected MSC and MV infected
MSC frozen/thawed cells have comparable antitumor ac-
tivities. However, since 109 TCID50 MV was well tolerated
in our Phase I trial with preliminary signs of activity, we
are proposing to deliver the cocktail of infected cells with
the 109 TCID50 of virus inoculum. Hence, our planned de-
livery strategy will involve thawing of certified MSC, mix-
ing with our GMP grade virus on the day of treatment, a
5 minute low speed centrifugation, incubation for 2 hours
at 37°C, followed by infusion of the cell-virus mixture into
the patient by a catheter in the peritoneal cavity. In
addition to MSC, other cells types are being developed as
carriers of proteins or viruses [9,26]. Neural stem cells are
being evaluated as carriers of oncolytic adenovirus for
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delivery of oncolytic vaccinia virus [50]. It is hoped that by
using cell carriers that home to tumors in conjunction with
the replication virotherapy, we could significantly amplify
the initial payload of cytotoxic agent to achieve significant
improvements in the outcome of cancer therapy.
Materials and methods
Isolation and culture of MSC from adipose tissues
All procedures involving human subjects were reviewed
and approved by the Mayo Clinic Institutional Review
Board (IRB). Human adipose tissues were obtained from
healthy donors as fat biopsies in an outpatient clinic.
Adipose tissues were also harvested from patients under-
going surgery for ovarian cancer resection via laparot-
omy. Following the usual midline skin incision, 2 cubic
cm of subcutaneous fat was excised prior to incision of
the fascia. The fat tissues were minced with surgical
scalpels and incubated in 0.075% collagenase type I
(Worthington Biochemical, Lakewood, NJ) for 90 min at
37°C. Digested tissue was centrifuged at 400 g for 5 min
with the pellet washed in PBS, passed through a 70 μm
cell strainer (BD Biosciences, San Jose, CA), and incubated
in red blood cell lysis buffer (154 mM NH4Cl, 10 mM
KHCO3, 0.1 mM EDTA). Cells were grown in T-175 cm2
flasks at a concentration of 1.0-2.5 ×103 cells/cm2 in
Advanced MEM with 5% PLTmax (Mill Creek Life
Sciences, Rochester, MN), 100 U/ml penicillin, 100 g/ml
streptomycin, and 2 mM L-glutamine (Invitrogen, Carlsbad,
CA, USA) in a 37°C 5% CO2 incubator for 3–4 days. When
cells were 60-80% confluent, they were passaged using
TrypLE (Trypsin Like Enzyme, Invitrogen). Cells were
frozen in aliquots in liquid nitrogen and stored until use.
Only low-passage cells (P5-7) were used for all the experi-
ments of this study, with the exception of the tumorigen-
icity study. These cells were phenotyped for typical MSC
cell markers, and were negative for Class II, CD14, CD45,
HLA-DR, and positive for CD44, CD73, CD90, CD105,
and Class I (A. Dietz, unpublished data).
Viruses, lentivectors and cell lines
Recombinant Edmonston strain measles virus expressing
Firefly Luciferase (FLuc), red fluorescent protein (RFP),
green fluorescent protein (GFP), or human sodium iod-
ide symporter gene (NIS) were generated as described
previously [20]. Briefly, African green monkey Vero pro-
ducer cells were infected with the viruses at MOI 0.02
and when 90% of the cells were in syncytia, the super-
natant was removed and the cells were scraped into
reduced serum medium, Opti-MEM (Invitrogen). The
cell pellet was frozen and thawed twice and clarified by
low speed centrifugation for 5 minutes. The viral super-
natants were frozen at ≤ 65°C until use. Measles viral
titers were determined by TCID50 titration on Vero cells.To generate the lentivectors, 293 T cells were co-
transfected with gag-pol expression plasmid pCMV8.91,
VSV.G envelope expression plasmid pMD-G, and vector
plasmid encoding FLuc, RFP, GFP or NIS [51]. Vector
supernatant was collected 48 hours later, filtered (0.45 um)
and frozen at ≤ 65°C until use. Human ovarian cancer cells,
SKOV3ip.1, stably expressing FLuc were maintained in
Alpha-MEM (Lonza, Allendale, NJ) supplemented with
20% fetal bovine serum (FBS, Gibco), 100 U mL-1 peni-
cillin-streptomycin, and 2 mM L-glutamine. Adipose derived
mesenchymal stem cells were maintained in Advanced
MEM (Invitrogen, Carlsbad, CA) supplemented with 5%
PLTmax, 2 U mL-1 heparin, 100 U mL-1 penicillin-strepto-
mycin, and 2 mM L-glutamine.
MSC x-CELLigence migration assay
Cells were grown in serum-free medium for 24 hours
(OptiMEM with 0.5% BSA). Pre-warmed media, with or
without chemoattractant, was added to the lower cham-
bers of the CIM-Plate 16 (Roche Applied Bioscience, In-
dianapolis, IN) according to manufacturer’s instructions.
Serum-free medium was placed in the top chamber to
hydrate the membrane. The plate was placed for 1 hour
in the incubator to obtain a background measurement.
MSC (2 × 104 cells) were added in the upper chamber
and the cells were allowed to settle to the bottom. Mea-
surements were taken every 5 minutes. To collect condi-
tioned media, normal culture media was removed from
cancer cell lines and replaced with OptiMEM with 0.5%
BSA for 48 hours after which the conditioned media was
collected and stored at −80°C until time of use.
Virus Infection and flow cytometry
MSC were infected in serum-free media (Opti-MEM) with
MV-GFP for 2 hours at 37°C while in constant rotation to
prevent cells from settling. Cells were infected at multipli-
city of infection (MOI) of 2 or 4. After incubation, MSC
were gently pelleted and supernatant removed. Cells
were plated and allowed to incubate at 37°C for
48 hours. Percent infect was determined by flow cyto-
metry on a FACScan (BD Dickinson, Franklin Lakes,
NJ) with a blue laser (excitation 488 nm). To prepare
cells for analysis, they were collected by centrifugation
and washed in PBS. The cells were then resuspended in
PBS containing 4% paraformaldehyde (Sigma, St. Louis,
MO). The cells were then incubated for 30 min at room
temp. Cells were washed twice in cold PBS, resuspended
in PBS and incubated overnight at 4°C, until acquisition
on the flow cytometer. On each sample, a minimum of
10,000 events was collected. Analysis of the data was per-
formed with CELLQuest software (BD). To enhance virus
infection, various physical methods were tested. For heat
shock, MSC were incubated briefly in a 42°C water bath
for 0, 5, or 10 minutes. Cells were cooled on ice for
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For DMSO treatment, MSC were treated with 4% DMSO
48 hours before, during, or after infection. To test the
impact of centrifugation, virus was added and the mix-
ture was centrifuged at 500, 1000, and 2000 × g for
various times and upon completion of centrifugation,
cell pellets were gently resuspended and the tubes were
placed at 37°C on a rotator. After 2 hours, cells were
plated in 12-well plates. MSC were allowed to incubate
at 37°C for 48 hours and percent infect was determined
by flow cytometry.
In vivo experiments
All procedures involving animals were approved by and
performed according to guidelines of the Institutional
Animal Care and Use Committee of Mayo Foundation.
For the safety experiment, female athymic mice were
given 2 x 106 SKOV3ip.1 FLuc or a cocktail of SKOV3ip.1
and MSC (2 × 106 of each cell type) intraperitoneally. For
imaging, mice were given i.p. injections of 150 mg/kg
D-luciferin 10 minutes before imaging for FLuc activity.
Whole abdominal bioluminescence signals reflecting
tumor burden (FLuc) were quantitated using the Living
Image 2.60 software according to manufacturer's proto-
col. Mice were euthanized when they developed ascites,
lost more than 20% of body weight or if they developed
a large injection site subcutaneous tumor of more than
10% body weight. All mice were euthanized at day 90
and Kaplan-Meier survival curves were plotted. The
log-rank test was used to examine the significance of
differences in the survival between groups. GraphPad
Prism and JMP v9.0 were used for the statistical calcu-
lations. P < 0.05 was considered significant.
For the tumorigenicity study, 30 SCID beige mice were
divided into three cohorts of ten. The test articles were
three separate lots of high passage hMSC collected and
purified from adipose tissue of three healthy donors.
Mice receiving hMSC were injected subcutaneously on
the right hind flank with approximately 2×107 hMSC/
200μL saline and those injected i.p. received approxi-
mately 4×107 hMSC/400μL saline. One mouse was used
as a control and received 5×106 SKOV3 tumor cells in
100 μL saline subcutaneously. Three mice were adminis-
tered hMSC subcutaneously and the remaining six were
administered hMSC i.p. Mice were monitored and tumors,
if present, were measured and recorded. Body weights
were collected. All mice were euthanized at or around
day 90 and necropsied. Another cohort of athymic mice
received 106 SKOV3ip.1 (n = 15 mice) or a cocktail of 106
SKOV3ip.1 and 106 MSC (n = 13 mice) ip. Survival curves
were plotted and compared.
For the therapy experiment, female athymic mice
(5–6 weeks of age; Harlan Laboratories; Indianapolis, IN)
were injected i.p. with 2×106 SKOV3ip.1 cells stablyexpressing Firefly Luciferase (SKOV3ip.1-FLuc). Mice
were imaged at day 7 using the Xenogen IVIS 200 bio-
luminescent imaging system (Xenogen, Alameda, CA).
One day before treatment, MSC were pre-infected with
MV-NIS (MOI 4.0) for two hours, virus was removed
and the cells were frozen in aliquots in liquid nitrogen
and stored until use. On day 0 a portion of MSC were
irradiated at 20 Gray before infection. MSC, irradiated
and non-irradiated, were infected with MV-NIS (MOI
4.0) for 2 h after which virus was removed. All MV-MSC
were combined with neutralizing serum for 30 minutes at
37°C. On day 0, all mice were passively immunized with an
i.p. injection of measles immune human pooled AB serum
(Valley Biomedical, Winchester, VA) 2 h before therapy.
The anti-MV titer of the purchased human AB serum was
300 EU/ml as determined by the Mayo Clinic Serology
Clinical Laboratory using their routine measles antibody
assay (Diamedix). In humans, a titer of > 20 EU/ml is
considered to be measles immune. The full plaque reduc-
tion neutralization titer of the serum is 1:256 against 250
TCID50 of MV-GFP on Vero cells [33]. Mice were injected
with the 3 different infected MSC platforms, naked virus
(MV-NIS, 105 viral particles per dose), or saline i.p. For
imaging, mice were given i.p. injections of 150 mg/kg
D-luciferin (Xenogen) 10 minutes before imaging for
firefly luciferase (FLuc) activity. Whole abdominal bio-
luminescence signals reflecting tumor burden (FLuc) were
quantitated using the Living Image 2.60 software (Xenogen)
according to manufacturer's protocol. For SPECT-CT im-
aging, mice received cells i.p., anesthesized by 2% isoflurane
inhalation and imaged on a small animal micro-SPECT-CT
machine (Gamma Medica, Northridge, CA). Mice were
euthanized when they developed ascites, lost more than
20% of body weight or if they developed a large injection
site subcutaneous tumor of more than 10% body weight.
All mice were euthanized at day 90 and Kaplan-Meier sur-
vival curves were plotted. The log-rank test was used to
examine the significance of differences in the survival be-
tween groups. GraphPad Prism (GraphPad Software, San
Diego, CA) was used for the statistical calculations. P < 0.05
was considered significant.
Competing interests
SJR and KWP are cofounders of Imanis Life Sciences (Rochester, MN). ABD is
a shareholder of Mill Creek Life Sciences, (Rochester, MN).
Authors’ contribution
EKM carried out the experimental studies and drafted the manuscript. GB
isolated and characterized the MSC. SCD and AM performed the surgeries,
harvested adipose tissues and ovarian tissues. KLK participated in the X-
Celligence migration assays. MJF, SJR, EG and AB participated in study
design. KWP conceived the study, performed analysis and drafted the
manuscript. All authors read and approved the final manuscript.
Acknowledgements
We thank Lukkana Suksanpaisan and Tracy Decklever for their expert help in
NIS imaging and Marla Sommerfield, Dr. Michelle Torres (Department of OB/
GYN) for recruitment of ovarian cancer patients and the Viral Vector
Mader et al. Journal of Translational Medicine 2013, 11:20 Page 13 of 14
http://www.translational-medicine.com/content/11/1/20Production Laboratory for MV-NIS virus. This project was supported by the
NIH/NCI (R01CA136547, R01CA129193) and the Mayo Clinic SPORE in Ovarian
Cancer P50CA136393.Funding
This project is funded by the Mayo Clinic SPORE in Ovarian Cancer
P50CA136393, R01CA136547, R01CA129193 and R01CA129966.
Author details
1Department of Molecular Medicine, Mayo Clinic, Rochester, MN 55905, USA.
2Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester,
MN 55905, USA. 3Department of Obstetrics and Gynecology, Mayo Clinic,
Rochester, MN 55905, USA. 4Department of Immunology, Mayo Clinic,
Rochester, MN 55905, USA. 5Guggenheim 18, Mayo Clinic, 200 First Street
SW, Rochester, MN 55905, USA.
Received: 18 October 2012 Accepted: 12 January 2013
Published: 24 January 2013References
1. Siegel R, Naishadham D, Jemal A: Cancer statistics, 2012. CA Cancer J Clin
2012, 62:10–29.
2. Markman M: Ovarian cancer in 2011: Mutations and non-inferiority
analyses show a way forward. Nat Rev Clin Oncol 2012, 9:69–70.
3. Naumann RW, Coleman RL: Management strategies for recurrent
platinum-resistant ovarian cancer. Drugs 2011, 71:1397–1412.
4. Aletti GD, Dowdy SC, Gostout BS, Jones MB, Stanhope CR, Wilson TO,
Podratz KC, Cliby WA: Aggressive surgical effort and improved survival in
advanced-stage ovarian cancer. Obstet Gynecol 2006, 107:77–85.
5. Le Blanc K, Mougiakakos D: Multipotent mesenchymal stromal cells and
the innate immune system. Nat Rev Immunol 2012, 12:383–396.
6. Trounson A, Thakar RG, Lomax G, Gibbons D: Clinical trials for stem cell
therapies. BMC Med 2011, 9:52.
7. Myers TJ, Granero-Molto F, Longobardi L, Li T, Yan Y, Spagnoli A:
Mesenchymal stem cells at the intersection of cell and gene therapy.
Expert Opin Biol Ther 2010, 10:1663–1679.
8. Dwyer RM, Kerin MJ: Mesenchymal stem cells and cancer: tumor-specific
delivery vehicles or therapeutic targets? Hum Gene Ther 2010,
21:1506–1512.
9. Russell SJ, Peng KW: The utility of cells as vehicles for oncolytic virus
therapies. Curr Opin Mol Ther 2008, 10:380–386.
10. Russell SJ, Peng KW, Bell JC: Oncolytic virotherapy. Nat Biotechnol 2012,
30:658–670.
11. Eager RM, Nemunaitis J: Clinical development directions in oncolytic viral
therapy. Cancer Gene Ther 2011, 18:305–317.
12. Kaufman HL, Bines SD: OPTIM trial: a Phase III trial of an oncolytic herpes
virus encoding GM-CSF for unresectable stage III or IV melanoma. Future
Oncol 2010, 6:941–949.
13. Ottolino-Perry K, Diallo JS, Lichty BD, Bell JC, McCart JA: Intelligent design:
combination therapy with oncolytic viruses. Molecular therapy: the journal
of the American Society of Gene Therapy 2010, 18:251–263.
14. Dingli D, Bergert ER, Bajzer Z, O'Connor MK, Russell SJ, Morris JC: Dynamic
iodide trapping by tumor cells expressing the thyroidal sodium iodide
symporter. Biochem Biophys Res Commun 2004, 325:157–166.
15. Wildner O, Morris JC, Vahanian NN, Ford H Jr, Ramsey WJ, Blaese RM:
Adenoviral vectors capable of replication improve the efficacy of
HSVtk/GCV suicide gene therapy of cancer. Gene Ther 1999, 6:57–62.
16. Russell SJ, Peng KW: Measles virus for cancer therapy. Curr Top Microbiol
Immunol 2009, 330:213–241.
17. Li H, Peng KW, Dingli D, Kratzke RA, Russell SJ: Oncolytic measles viruses
encoding interferon beta and the thyroidal sodium iodide symporter
gene for mesothelioma virotherapy. Cancer Gene Ther 2010, 17:550–558.
18. Phuong LK, Allen C, Peng KW, Giannini C, Greiner S, TenEyck CJ, Mishra PK,
Macura SI, Russell SJ, Galanis EC: Use of a vaccine strain of measles virus
genetically engineered to produce carcinoembryonic antigen as a novel
therapeutic agent against glioblastoma multiforme. Cancer Res 2003,
63:2462–2469.
19. Peng KW, TenEyck CJ, Galanis E, Kalli KR, Hartmann LC, Russell SJ:
Intraperitoneal therapy of ovarian cancer using an engineered measles
virus. Cancer Res 2002, 62:4656–4662.20. Peng KW, Ahmann GJ, Pham L, Greipp PR, Cattaneo R, Russell SJ: Systemic
therapy of myeloma xenografts by an attenuated measles virus. Blood
2001, 98:2002–2007.
21. Msaouel P, Dispenzieri A, Galanis E: Clinical testing of engineered
oncolytic measles virus strains in the treatment of cancer: an overview.
Curr Opin Mol Ther 2009, 11:43–53.
22. Myers RM, Greiner SM, Harvey ME, Griesmann G, Kuffel MJ, Buhrow SA, Reid
JM, Federspiel M, Ames MM, Dingli D, et al: Preclinical pharmacology and
toxicology of intravenous MV-NIS, an oncolytic measles virus
administered with or without cyclophosphamide. Clin Pharmacol Ther
2007, 82:700–710.
23. Galanis E, Hartmann LC, Cliby WA, Long HJ, Peethambaram PP, Barrette BA,
Kaur JS, Haluska PJ Jr, Aderca I, Zollman PJ, et al: Phase I trial of
intraperitoneal administration of an oncolytic measles virus strain
engineered to express carcinoembryonic antigen for recurrent ovarian
cancer. Cancer Res 2010, 70:875–882.
24. Markman M, Webster K, Zanotti K, Peterson G, Kulp B, Belinson J: Survival
following the documentation of platinum and taxane resistance in
ovarian cancer: a single institution experience involving multiple phase
2 clinical trials. Gynecol Oncol 2004, 93:699–701.
25. Hasegawa K, Pham L, O'Connor MK, Federspiel MJ, Russell SJ, Peng KW:
Dual therapy of ovarian cancer using measles viruses expressing
carcinoembryonic antigen and sodium iodide symporter. Clinical cancer
research: an official journal of the American Association for Cancer Research
2006, 12:1868–1875.
26. Thorne SH, Contag CH: Combining immune cell and viral therapy for the
treatment of cancer. Cellular and molecular life sciences: CMLS 2007,
64:1449–1451.
27. Power AT, Bell JC: Cell-based delivery of oncolytic viruses: a new strategic
alliance for a biological strike against cancer. Molecular therapy: the
journal of the American Society of Gene Therapy 2007, 15:660–665.
28. Nakashima H, Kaur B, Chiocca EA: Directing systemic oncolytic viral
delivery to tumors via carrier cells. Cytokine Growth Factor Rev 2010,
21:119–126.
29. Dembinski JL, Spaeth EL, Fueyo J, Gomez-Manzano C, Studeny M, Andreeff
M, Marini FC: Reduction of nontarget infection and systemic toxicity by
targeted delivery of conditionally replicating viruses transported in
mesenchymal stem cells. Cancer Gene Ther 2010, 17:289–297.
30. Ahmed AU, Tyler MA, Thaci B, Alexiades NG, Han Y, Ulasov IV, Lesniak MS: A
comparative study of neural and mesenchymal stem cell-based carriers
for oncolytic adenovirus in a model of malignant glioma. Mol Pharm
2011, 8:1559–1572.
31. Komarova S, Kawakami Y, Stoff-Khalili MA, Curiel DT, Pereboeva L:
Mesenchymal progenitor cells as cellular vehicles for delivery of
oncolytic adenoviruses. Mol Cancer Ther 2006, 5:755–766.
32. Dittmar T, Entschladen F: Migratory Properties of Mesenchymal Stem
Cells. Adv Biochem Eng Biotechnol 2012, doi:10.1007/10_2012_144.
33. Mader EK, Maeyama Y, Lin Y, Butler GW, Russell HM, Galanis E, Russell SJ,
Dietz AB, Peng KW: Mesenchymal stem cell carriers protect oncolytic
measles viruses from antibody neutralization in an orthotopic ovarian
cancer therapy model. Clinical cancer research: an official journal of the
American Association for Cancer Research 2009, 15:7246–7255.
34. Crespo-Diaz R, Behfar A, Butler GW, Padley DJ, Sarr MG, Bartunek J, Dietz AB,
Terzic A: Platelet lysate consisting of a natural repair proteome supports
human mesenchymal stem cell proliferation and chromosomal stability.
Cell Transplant 2011, 20:797–811.
35. Dohan O, De la Vieja A, Paroder V, Riedel C, Artani M, Reed M, Ginter CS,
Carrasco N: The sodium/iodide Symporter (NIS): characterization,
regulation, and medical significance. Endocr Rev 2003, 24:48–77.
36. Lech PJ, Russell SJ: Use of attenuated paramyxoviruses for cancer
therapy. Expert Rev Vaccines 2010, 9:1275–1302.
37. Peng KW, Facteau S, Wegman T, O'Kane D, Russell SJ: Non-invasive in vivo
monitoring of trackable viruses expressing soluble marker peptides.
Nat Med 2002, 8:527–531.
38. Ong HT, Hasegawa K, Dietz AB, Russell SJ, Peng KW: Evaluation of T cells as
carriers for systemic measles virotherapy in the presence of antiviral
antibodies. Gene Ther 2007, 14:324–333.
39. Peng KW, Dogan A, Vrana J, Liu C, Ong HT, Kumar S, Dispenzieri A, Dietz AB,
Russell SJ: Tumor-associated macrophages infiltrate plasmacytomas and
can serve as cell carriers for oncolytic measles virotherapy of
disseminated myeloma. Am J Hematol 2009, 84:401–407.
Mader et al. Journal of Translational Medicine 2013, 11:20 Page 14 of 14
http://www.translational-medicine.com/content/11/1/2040. Lee JS, Hong JM, Moon GJ, Lee PH, Ahn YH, Bang OY: A long-term follow-up
study of intravenous autologous mesenchymal stem cell transplantation in
patients with ischemic stroke. Stem Cells 2010, 28:1099–1106.
41. Karussis D, Karageorgiou C, Vaknin-Dembinsky A, Gowda-Kurkalli B, Gomori
JM, Kassis I, Bulte JW, Petrou P, Ben-Hur T, Abramsky O, Slavin S: Safety and
immunological effects of mesenchymal stem cell transplantation in
patients with multiple sclerosis and amyotrophic lateral sclerosis. Arch
Neurol 2010, 67:1187–1194.
42. Hare JM, Traverse JH, Henry TD, Dib N, Strumpf RK, Schulman SP,
Gerstenblith G, DeMaria AN, Denktas AE, Gammon RS, et al: A randomized,
double-blind, placebo-controlled, dose-escalation study of intravenous
adult human mesenchymal stem cells (prochymal) after acute
myocardial infarction. J Am Coll Cardiol 2009, 54:2277–2286.
43. Ra JC, Shin IS, Kim SH, Kang SK, Kang BC, Lee HY, Kim YJ, Jo JY, Yoon EJ,
Choi HJ, Kwon E: Safety of intravenous infusion of human adipose
tissue-derived mesenchymal stem cells in animals and humans. Stem
Cells Dev 2011, 20:1297–1308.
44. Willis MJ, Bird LM, Dell'Aquilla M, Jones MC: Expanding the phenotype of
mosaic trisomy 20. Am J Med Genet A 2008, 146:330–336.
45. Lechner JF, Neft RE, Gilliland FD, Crowell RE, Auckley DH, Temes RT, Belinsky
SA: Individuals at high risk for lung cancer have airway epithelial cells
with chromosome aberrations frequently found in lung tumor cells.
In Vivo 1998, 12:23–26.
46. Lee JM: The role of protein elongation factor eEF1A2 in ovarian cancer.
Reproductive biology and endocrinology: RB&E 2003, 1:69.
47. Tanner MM, Grenman S, Koul A, Johannsson O, Meltzer P, Pejovic T, Borg A,
Isola JJ: Frequent amplification of chromosomal region 20q12-q13 in
ovarian cancer. Clinical cancer research: an official journal of the American
Association for Cancer Research 2000, 6:1833–1839.
48. Ahmed AU, Ulasov IV, Mercer RW, Lesniak MS: Maintaining and loading
neural stem cells for delivery of oncolytic adenovirus to brain tumors.
Methods Mol Biol 2012, 797:97–109.
49. Thaci B, Ahmed AU, Ulasov IV, Tobias AL, Han Y, Aboody KS, Lesniak MS:
Pharmacokinetic study of neural stem cell-based cell carrier for oncolytic
virotherapy: targeted delivery of the therapeutic payload in an
orthotopic brain tumor model. Cancer Gene Ther 2012, 19:431–442.
50. Thorne SH, Negrin RS, Contag CH: Synergistic antitumor effects of
immune cell-viral biotherapy. Science 2006, 311:1780–1784.
51. Peng KW, Pham L, Ye H, Zufferey R, Trono D, Cosset FL, Russell SJ: Organ
distribution of gene expression after intravenous infusion of targeted
and untargeted lentiviral vectors. Gene Ther 2001, 8:1456–1463.
doi:10.1186/1479-5876-11-20
Cite this article as: Mader et al.: Optimizing patient derived
mesenchymal stem cells as virus carriers for a Phase I clinical trial in
ovarian cancer. Journal of Translational Medicine 2013 11:20.Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
